Majority of Canadians living with advanced stage Parkinson’s Disease will now have publicly funded access to NEUPRO®.

BREAKING NEWS! UCB Canada just announced that the majority of Canadians living with advanced stage Parkinson’s Disease will now have publicly funded access to NEUPRO®. The drug helps to alleviate debilitating symptoms including tremors, slow movement and stiffness.

“It’s encouraging for patients living with Parkinson’s and their caregivers to know that they have treatment options at every stage of this life-changing disease,” says Joyce Gordon, Chief Executive Officer, Parkinson Canada. “As a condition that manifests itself differently from person to person, and gets worse over time, symptom control is critical.”

To learn more about the funding of NEUPRO® for Canadians battling APD, read UCB Canada Inc.’s news release.